Insulet Corporation (PODD)
After hours:
| Previous close | 218.97 |
| Open | 218.00 |
| Bid | 215.00 x 800 |
| Ask | 275.00 x 900 |
| Day's range | 218.00 - 227.95 |
| 52-week range | 181.00 - 324.81 |
| Volume | |
| Avg. volume | 535,058 |
| Market cap | 15.791B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 356.38 |
| EPS (TTM) | 0.64 |
| Earnings date | 03 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 273.62 |
- Simply Wall St.
Insulet (NASDAQ:PODD) shareholders are still up 307% over 5 years despite pulling back 9.2% in the past week
While Insulet Corporation ( NASDAQ:PODD ) shareholders are probably generally happy, the stock hasn't had particularly...
- Zacks
Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5
Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.
- Business Wire
Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years
ACTON, Mass., June 03, 2022--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new Omnipod® 5 Automated Insulin Delivery System (Omnipod 5) study results for very young children with type 1 diabetes. Omnipod 5, the first tubeless, wearable automated insulin delivery (AID) system in the U.S., significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 yea
